Insider Trades86 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Sell | ADPT | Susan Bobulsky | Chief Commercial Officer, MRD | 3,000 | $25.00 | $3.9B | -9.94% | +101.67% | $75.0K | -0.75% | 10b5-1 | Buy Now |
| Jul 30, 2026 | Sell | ADPT | Susan Bobulsky | Chief Commercial Officer, MRD | 1,299 | $24.00 | $3.9B | -9.94% | +101.67% | $31.2K | -0.32% | 10b5-1 | Buy Now |
| Jul 21, 2026 | Sell | ADPT | Harlan S Robins | Chief Scientific Officer | 777,200 | $16.27 | $3.9B | -9.94% | +101.67% | $12.6M | -6.20% | 10b5-1 | Buy Now |
| Jul 16, 2026 | Sell | ADPT | Susan Bobulsky | Chief Commercial Officer, MRD | 5,000 | $23.00 | $3.9B | -9.94% | +101.67% | $115.0K | -1.23% | 10b5-1 | Buy Now |
| Jul 15, 2026 | Sell | ADPT | Francis Lo | Chief People Officer | 211,524 | $15.75 | $3.9B | -9.94% | +101.67% | $3.3M | +0.00% | 10b5-1 | Buy Now |
| Jul 2, 2026 | Sell | ADPT | Harlan S Robins | Chief Scientific Officer | 386,240 | $22.01 | $3.9B | -9.94% | +101.67% | $8.5M | -15.01% | 10b5-1 | Buy Now |
| Jul 1, 2026 | Sell | ADPT | Susan Bobulsky | Chief Commercial Officer, MRD | 487 | $22.00 | $3.9B | -9.94% | +101.67% | $10.7K | -0.12% | 10b5-1 | Buy Now |
| Jul 1, 2026 | Sell | ADPT | Francis Lo | Chief People Officer | 171,463 | $16.44 | $3.9B | -9.94% | +101.67% | $2.8M | -0.55% | 10b5-1 | Buy Now |
| Jun 26, 2026 | Sell | ADPT | Sharon Benzeno | Chief Commercial Ofc Imm Med | 280,131 | $15.67 | $3.9B | -9.94% | +101.67% | $4.4M | -2.20% | 10b5-1 | Buy Now |
| Jun 25, 2026 | Sell | ADPT | Susan Bobulsky | Chief Commercial Officer, MRD | 5,000 | $20.50 | $3.9B | -9.94% | +101.67% | $102.5K | -1.21% | 10b5-1 | Buy Now |
| Jun 15, 2026 | Sell | ADPT | Harlan S Robins | Chief Scientific Officer | 106,160 | $17.41 | $3.9B | -9.94% | +101.67% | $1.8M | -3.63% | 10b5-1 | Buy Now |
| Jun 11, 2026 | Sell | ADPT | Susan Bobulsky | Chief Commercial Officer, MRD | 5,000 | $19.00 | $3.9B | -9.94% | +101.67% | $95.0K | -1.20% | 10b5-1 | Buy Now |
| Jun 4, 2026 | Sell | ADPT | Susan Bobulsky | Chief Commercial Officer, MRD | 11,000 | $18.00 | $3.9B | -9.94% | +101.67% | $198.0K | -2.57% | 10b5-1 | Buy Now |
| Jun 4, 2026 | Sell | ADPT | Francis Lo | Chief People Officer | 59,262 | $14.64 | $3.9B | -9.94% | +101.67% | $867.9K | -1.07% | 10b5-1 | Buy Now |
| May 18, 2026 | Sell | ADPT | Kyle Piskel | Chief Financial Officer | 3,115 | $13.04 | $3.9B | -9.94% | +101.67% | $40.6K | -1.20% | — | Buy Now |
| Apr 27, 2026 | Sell | ADPT | Julie Rubinstein | President and COO | 33,744 | $11.72 | $3.9B | -9.94% | +101.67% | $395.3K | -0.53% | 10b5-1 | Buy Now |
| Apr 22, 2026 | Sell | ADPT | Julie Rubinstein | President and COO | 101,346 | $11.57 | $3.9B | -9.94% | +101.67% | $1.2M | -0.50% | 10b5-1 | Buy Now |
| Apr 17, 2026 | Sell | ADPT | Julie Rubinstein | President and COO | 125,108 | $12.20 | $3.9B | -9.94% | +101.67% | $1.5M | -0.36% | 10b5-1 | Buy Now |
| Apr 14, 2026 | Sell | ADPT | Julie Rubinstein | President and COO | 101,346 | $11.84 | $3.9B | -9.94% | +101.67% | $1.2M | -0.43% | 10b5-1 | Buy Now |
| Apr 9, 2026 | Sell | ADPT | Julie Rubinstein | President and COO | 101,346 | $10.73 | $3.9B | -9.94% | +101.67% | $1.1M | -0.29% | 10b5-1 | Buy Now |
| Apr 8, 2026 | Sell | ADPT | Harlan S Robins | Chief Scientific Officer | 10,000 | $14.85 | $3.9B | -9.94% | +101.67% | $148.5K | -0.66% | 10b5-1 | Buy Now |
| Apr 8, 2026 | Sell | ADPT | Francis Lo | Chief People Officer | 24,908 | $14.03 | $3.9B | -9.94% | +101.67% | $349.4K | -3.00% | 10b5-1 | Buy Now |
| Apr 6, 2026 | Sell | ADPT | Julie Rubinstein | President and COO | 125,108 | $11.64 | $3.9B | -9.94% | +101.67% | $1.5M | -0.31% | 10b5-1 | Buy Now |
| Apr 6, 2026 | Sell | ADPT | Chad M Robins | CEO and Chairman | 120,595 | $14.65 | $3.9B | -9.94% | +101.67% | $1.8M | -2.67% | 10b5-1 | Buy Now |
| Apr 1, 2026 | Sell | ADPT | Julie Rubinstein | President and COO | 67,564 | $11.36 | $3.9B | -9.94% | +101.67% | $767.8K | -0.43% | 10b5-1 | Buy Now |
| Mar 27, 2026 | Sell | ADPT | Julie Rubinstein | President and COO | 101,346 | $10.58 | $3.9B | -9.94% | +101.67% | $1.1M | -0.35% | 10b5-1 | Buy Now |
| Mar 24, 2026 | Sell | ADPT | Julie Rubinstein | President and COO | 101,346 | $11.08 | $3.9B | -9.94% | +101.67% | $1.1M | -0.38% | 10b5-1 | Buy Now |
| Mar 19, 2026 | Sell | ADPT | Julie Rubinstein | President and COO | 101,346 | $10.63 | $3.9B | -9.94% | +101.67% | $1.1M | -0.33% | 10b5-1 | Buy Now |
| Mar 16, 2026 | Sell | ADPT | Julie Rubinstein | President and COO | 101,346 | $10.38 | $3.9B | -9.94% | +101.67% | $1.1M | -0.41% | 10b5-1 | Buy Now |
| Mar 11, 2026 | Sell | ADPT | Kyle Piskel | Chief Financial Officer | 18,672 | $13.17 | $3.9B | -9.94% | +101.67% | $245.9K | -6.70% | — | Buy Now |
| Mar 11, 2026 | Sell | ADPT | Francis Lo | Chief People Officer | 30,593 | $14.08 | $3.9B | -9.94% | +101.67% | $430.7K | -9.50% | 10b5-1 | Buy Now |
| Mar 11, 2026 | Sell | ADPT | Susan Bobulsky | Chief Commercial Officer, MRD | 41,338 | $13.17 | $3.9B | -9.94% | +101.67% | $544.4K | -8.81% | — | Buy Now |
| Mar 11, 2026 | Sell | ADPT | Sharon Benzeno | Chief Commercial Ofc Imm Med | 63,103 | $13.17 | $3.9B | -9.94% | +101.67% | $831.1K | -18.79% | — | Buy Now |
| Mar 11, 2026 | Sell | ADPT | Julie Rubinstein | President and COO | 223,869 | $11.90 | $3.9B | -9.94% | +101.67% | $2.7M | -2.99% | 10b5-1 | Buy Now |
| Mar 11, 2026 | Sell | ADPT | Chad M Robins | CEO and Chairman | 470,167 | $13.17 | $3.9B | -9.94% | +101.67% | $6.2M | -8.70% | — | Buy Now |
| Mar 11, 2026 | Sell | ADPT | Harlan S Robins | Chief Scientific Officer | 470,266 | $13.17 | $3.9B | -9.94% | +101.67% | $6.2M | -12.23% | — | Buy Now |
| Mar 6, 2026 | Sell | ADPT | Julie Rubinstein | President and COO | 149,670 | $11.99 | $3.9B | -9.94% | +101.67% | $1.8M | -0.17% | 10b5-1 | Buy Now |
| Mar 5, 2026 | Sell | ADPT | Francis Lo | Chief People Officer | 38,074 | $15.09 | $3.9B | -9.94% | +101.67% | $574.5K | -10.57% | — | Buy Now |
| Mar 3, 2026 | Sell | ADPT | Julie Rubinstein | President and COO | 172,632 | $12.83 | $3.9B | -9.94% | +101.67% | $2.2M | -0.17% | 10b5-1 | Buy Now |
| Mar 2, 2026 | Sell | ADPT | Harlan S Robins | Chief Scientific Officer | 24,233 | $16.19 | $3.9B | -9.94% | +101.67% | $392.3K | -1.03% | 10b5-1 | Buy Now |
| Feb 27, 2026 | Sell | ADPT | Chad M Robins | CEO and Chairman | 524,998 | $15.85 | $3.9B | -9.94% | +101.67% | $8.3M | -6.06% | 10b5-1 | Buy Now |
| Feb 4, 2026 | Sell | ADPT | Kyle Piskel | Chief Financial Officer | 4,290 | $15.30 | $3.9B | -9.94% | +101.67% | $65.6K | +0.00% | 10b5-1 | Buy Now |
| Feb 2, 2026 | Sell | ADPT | Harlan S Robins | Chief Scientific Officer | 42,788 | $18.68 | $3.9B | -9.94% | +101.67% | $799.1K | -1.78% | 10b5-1 | Buy Now |
| Feb 2, 2026 | Sell | ADPT | Chad M Robins | CEO and Chairman | 124,998 | $18.44 | $3.9B | -9.94% | +101.67% | $2.3M | -4.84% | 10b5-1 | Buy Now |
| Jan 12, 2026 | Sell | ADPT | Kyle Piskel | Chief Financial Officer | 8,580 | $15.07 | $3.9B | -9.94% | +101.67% | $129.3K | +0.00% | 10b5-1 | Buy Now |
| Jan 12, 2026 | Sell | ADPT | Francis Lo | Chief People Officer | 159,180 | $12.72 | $3.9B | -9.94% | +101.67% | $2.0M | +0.00% | 10b5-1 | Buy Now |
| Jan 6, 2026 | Sell | ADPT | Harlan S Robins | Chief Scientific Officer | 10,000 | $16.44 | $3.9B | -9.94% | +101.67% | $164.4K | -0.81% | 10b5-1 | Buy Now |
| Jan 5, 2026 | Sell | ADPT | Chad M Robins | CEO and Chairman | 124,998 | $15.59 | $3.9B | -9.94% | +101.67% | $1.9M | -4.61% | 10b5-1 | Buy Now |
| Jan 2, 2026 | Sell | ADPT | Francis Lo | Chief People Officer | 6,250 | $10.03 | $3.9B | -9.94% | +101.67% | $62.7K | +0.00% | 10b5-1 | Buy Now |
| Dec 22, 2025 | Sell | ADPT | Francis Lo | Chief People Officer | 8,788 | $11.78 | $3.9B | -9.94% | +101.67% | $103.5K | +0.00% | 10b5-1 | Buy Now |
| Dec 22, 2025 | Sell | ADPT | Francis Lo | Chief People Officer | 8,788 | $12.34 | $3.9B | -9.94% | +101.67% | $108.4K | +0.00% | 10b5-1 | Buy Now |
| Dec 15, 2025 | Sell | ADPT | Francis Lo | Chief People Officer | 210,912 | $11.34 | $3.9B | -9.94% | +101.67% | $2.4M | -0.91% | 10b5-1 | Buy Now |
| Dec 4, 2025 | Sell | ADPT | Sharon Benzeno | Chief Commercial Ofc Imm Med | 25,208 | $12.54 | $3.9B | -9.94% | +101.67% | $316.2K | +0.00% | 10b5-1 | Buy Now |
| Dec 3, 2025 | Sell | ADPT | Harlan S Robins | Chief Scientific Officer | 37,212 | $18.07 | $3.9B | -9.94% | +101.67% | $672.5K | -1.48% | 10b5-1 | Buy Now |
| Nov 28, 2025 | Sell | ADPT | Kyle Piskel | Chief Financial Officer | 272,934 | $16.23 | $3.9B | -9.94% | +101.67% | $4.4M | -4.31% | 10b5-1 | Buy Now |
| Nov 26, 2025 | Sell | ADPT | Chad M Robins | CEO and Chairman | 160,734 | $19.10 | $3.9B | -9.94% | +101.67% | $3.1M | -2.82% | 10b5-1 | Buy Now |
| Nov 20, 2025 | Sell | ADPT | Sharon Benzeno | Chief Commercial Ofc Imm Med | 1,116,872 | $13.08 | $3.9B | -9.94% | +101.67% | $14.6M | -2.06% | 10b5-1 | Buy Now |
| Nov 17, 2025 | Sell | ADPT | Kyle Piskel | Chief Financial Officer | 238 | $14.05 | $3.9B | -9.94% | +101.67% | $3.3K | -0.09% | — | Buy Now |
| Nov 10, 2025 | Sell | ADPT | Harlan S Robins | Chief Scientific Officer | 10,000 | $14.82 | $3.9B | -9.94% | +101.67% | $148.2K | -0.78% | 10b5-1 | Buy Now |
| Nov 10, 2025 | Sell | ADPT | Chad M Robins | CEO and Chairman | 89,265 | $14.73 | $3.9B | -9.94% | +101.67% | $1.3M | -1.03% | 10b5-1 | Buy Now |
| May 16, 2025 | Sell | ADPT | Kyle Piskel | Chief Financial Officer | 1,929 | $8.89 | $3.9B | -9.94% | +101.67% | $17.1K | -0.69% | — | Buy Now |
| May 16, 2025 | Sell | ADPT | Kyle Piskel | Chief Financial Officer | 1,929 | $8.89 | $3.9B | -9.94% | +101.67% | $17.1K | -0.71% | — | Buy Now |
| May 1, 2025 | Sell | ADPT | Harlan S Robins | Chief Scientific Officer | 136,824 | $6.83 | $3.9B | -9.94% | +101.67% | $935.2K | +0.00% | 10b5-1 | Buy Now |
| Mar 24, 2025 | Sell | ADPT | Harlan S Robins | Chief Scientific Officer | 3,396 | $7.66 | $3.9B | -9.94% | +101.67% | $26.0K | +0.00% | 10b5-1 | Buy Now |
| Mar 14, 2025 | Buy | ADPT | Kyle Piskel | Chief Financial Officer | 2,500 | $6.32 | $3.9B | -9.94% | +101.67% | $15.8K | +0.93% | — | Buy Now |
| Mar 5, 2025 | Sell | ADPT | Kyle Piskel | Chief Financial Officer | 10,320 | $6.98 | $3.9B | -9.94% | +101.67% | $72.1K | -1.24% | — | Buy Now |
| Mar 5, 2025 | Sell | ADPT | Francis Lo | Chief People Officer | 20,875 | $6.99 | $3.9B | -9.94% | +101.67% | $145.8K | -2.45% | — | Buy Now |
| Mar 5, 2025 | Sell | ADPT | Susan Bobulsky | Chief Commercial Officer, MRD | 26,023 | $6.98 | $3.9B | -9.94% | +101.67% | $181.6K | -4.70% | — | Buy Now |
| Mar 5, 2025 | Sell | ADPT | Sharon Benzeno | Chief Commercial Ofc Imm Med | 44,665 | $6.98 | $3.9B | -9.94% | +101.67% | $311.8K | -4.47% | — | Buy Now |
| Mar 5, 2025 | Sell | ADPT | Julie Rubinstein | President and COO | 59,505 | $6.98 | $3.9B | -9.94% | +101.67% | $415.5K | -4.74% | — | Buy Now |
| Mar 5, 2025 | Sell | ADPT | Harlan S Robins | Chief Scientific Officer | 96,656 | $6.99 | $3.9B | -9.94% | +101.67% | $675.2K | -3.56% | — | Buy Now |
| Mar 5, 2025 | Sell | ADPT | Chad M Robins | CEO and Chairman | 219,569 | $7.29 | $3.9B | -9.94% | +101.67% | $1.6M | -2.48% | — | Buy Now |
| Feb 19, 2025 | Sell | ADPT | Chad M Robins | CEO and Chairman | 570,374 | $7.39 | $3.9B | -9.94% | +101.67% | $4.2M | +0.00% | 10b5-1 | Buy Now |
| Feb 13, 2025 | Sell | ADPT | Chad M Robins | CEO and Chairman | 940,736 | $7.40 | $3.9B | -9.94% | +101.67% | $7.0M | +0.00% | 10b5-1 | Buy Now |
| Nov 18, 2024 | Sell | ADPT | Kyle Piskel | Chief Financial Officer | 248 | $4.98 | $3.9B | -9.94% | +101.67% | $1.2K | -0.16% | — | Buy Now |
| Oct 8, 2024 | Buy | ADPT | Susan Bobulsky | Chief Commercial Officer, MRD | 5,000 | $1.98 | $3.9B | -9.94% | +101.67% | $9.9K | +2.01% | — | Buy Now |
| Aug 22, 2024 | Sell | ADPT | Stacy L Taylor | SVP and General Counsel | 26,922 | $4.50 | $3.9B | -9.94% | +101.67% | $121.1K | -16.19% | 10b5-1 | Buy Now |
| Mar 5, 2024 | Sell | ADPT | Kyle Piskel | Principal Accounting Officer | 7,727 | $3.43 | $3.9B | -9.94% | +101.67% | $26.5K | -5.90% | — | Buy Now |
| Mar 5, 2024 | Sell | ADPT | Susan Bobulsky | Chief Commercial Officer, MRD | 12,991 | $3.44 | $3.9B | -9.94% | +101.67% | $44.6K | -1.81% | — | Buy Now |
| Mar 5, 2024 | Sell | ADPT | Stacy L Taylor | SVP and General Counsel | 13,381 | $3.43 | $3.9B | -9.94% | +101.67% | $46.0K | -3.24% | — | Buy Now |
| Mar 5, 2024 | Sell | ADPT | Francis Lo | Chief People Officer | 14,700 | $3.43 | $3.9B | -9.94% | +101.67% | $50.4K | -2.18% | — | Buy Now |
| Mar 5, 2024 | Sell | ADPT | Tycho Peterson | Chief Financial Officer | 15,456 | $3.44 | $3.9B | -9.94% | +101.67% | $53.2K | -2.83% | — | Buy Now |
| Mar 5, 2024 | Sell | ADPT | Sharon Benzeno | Chief Commercial Ofc Imm Med | 29,390 | $3.44 | $3.9B | -9.94% | +101.67% | $101.0K | -3.26% | — | Buy Now |
| Mar 5, 2024 | Sell | ADPT | Julie Rubinstein | President | 39,070 | $3.47 | $3.9B | -9.94% | +101.67% | $135.8K | -3.91% | — | Buy Now |
| Mar 5, 2024 | Sell | ADPT | Chad M Robins | CEO and Chairman | 48,673 | $3.43 | $3.9B | -9.94% | +101.67% | $167.0K | -0.93% | — | Buy Now |
| Nov 16, 2023 | Sell | ADPT | Kyle Piskel | Principal Accounting Officer | 259 | $4.13 | $3.9B | -9.94% | +101.67% | $1.1K | -0.30% | — | Buy Now |